niacinamide has been researched along with Cholangiocarcinoma in 28 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy." | 9.17 | A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. ( Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH, 2013) |
| "We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma." | 9.14 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010) |
| " Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug." | 7.79 | Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. ( Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J, 2013) |
| "A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ε-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo." | 7.79 | Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells. ( Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM, 2013) |
| "Sorafenib was effective and well-tolerated in a patient with advanced cholangiocellular carcinoma." | 7.77 | Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. ( Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F, 2011) |
| "To study the effects of sorafenib on lymphangiogenesis in transplanted human cholangiocarcinoma in nude mice." | 7.76 | [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice]. ( Huang, FK; Shi, Z, 2010) |
| "Two female patients with biopsy-proven multifocal moderately differentiated cholangiocarcinoma received single-agent sorafenib at standard doses." | 7.74 | Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. ( Foreman, B; Hicks, MD; LaRocca, RV; Mull, L, 2007) |
| "To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib." | 7.74 | Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| " The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)." | 6.84 | Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017) |
| "Sorafenib and erlotinib were administered continuously at 400 mg BID and 100 mg daily, respectively." | 6.79 | S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. ( Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB, 2014) |
| "Sorafenib was administered at 400 mg po twice daily continuously." | 6.77 | SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. ( Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ, 2012) |
| "Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay." | 5.42 | Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. ( Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M, 2015) |
| "Sorafenib treatment of three human CCA cell lines resulted in Tyr(705) phospho-STAT3 dephosphorylation." | 5.35 | Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. ( Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW, 2009) |
| "Sorafenib treatment dose-dependently blocked growth-factor-induced activation of the MAPKP and inhibited the proliferation of EGI-1 and TFK-1 CC cells in a time- and dose-dependent manner." | 5.34 | Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| "This study evaluated the addition of sorafenib to gemcitabine and cisplatin in biliary adenocarcinoma first-line therapy." | 5.17 | A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas. ( Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH, 2013) |
| "We conducted a phase II trial of single-agent sorafenib in patients with advanced biliary tract carcinoma." | 5.14 | Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. ( Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S, 2010) |
| " Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug." | 3.79 | Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib. ( Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J, 2013) |
| "A sorafenib-coated metal stent was prepared using an electrospray system with the aid of poly(ε-caprolactone) (PCL), and then its anticancer activity was investigated using human cholangiocellular carcinoma (HuCC)-T1 cells in vitro and a mouse tumor xenograft model in vivo." | 3.79 | Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells. ( Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM, 2013) |
| "Sorafenib was effective and well-tolerated in a patient with advanced cholangiocellular carcinoma." | 3.77 | Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report. ( Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F, 2011) |
| "To study the effects of sorafenib on lymphangiogenesis in transplanted human cholangiocarcinoma in nude mice." | 3.76 | [Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice]. ( Huang, FK; Shi, Z, 2010) |
| "Two female patients with biopsy-proven multifocal moderately differentiated cholangiocarcinoma received single-agent sorafenib at standard doses." | 3.74 | Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. ( Foreman, B; Hicks, MD; LaRocca, RV; Mull, L, 2007) |
| "To investigate the antiproliferative effect of the histone deacetylase (HDAC) inhibitor MS-275 on cholangiocarcinoma cells alone and in combination with conventional cytostatic drugs (gemcitabine or doxorubicin) or the novel anticancer agents sorafenib or bortezomib." | 3.74 | Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| "EVESOR is a multiparameter dose-escalation phase I trial investigating different doses and dosing schedules, with the final objective of generating data for modeling and simulation." | 3.30 | Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors. ( Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B, 2023) |
| "The dose escalation, confirmation, and expansion results support the dosing of merestinib at 120 mg once daily, based on acceptable exposure and safety at this dose." | 2.90 | First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. ( Birnbaum, A; Cohen, RB; Denlinger, CS; Giles, J; He, AR; Hwang, J; Lewis, N; Moser, B; Mynderse, M; Niland, M; Plimack, ER; Sama, A; Sato, T; Walgren, R; Wallin, J; Zhang, W, 2019) |
| " The primary endpoint was disease control rate (DCR) at week 12, and the secondary endpoints included time to progression (TTP), progression-free survival (PFS), overall survival (OS), duration of therapy (DOT), and adverse events (AEs)." | 2.84 | Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. ( Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T, 2017) |
| "Sorafenib and erlotinib were administered continuously at 400 mg BID and 100 mg daily, respectively." | 2.79 | S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. ( Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB, 2014) |
| "Sorafenib was administered at 400 mg po twice daily continuously." | 2.77 | SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. ( Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ, 2012) |
| "Viability of HepaRG (hepatocellular carcinoma) and HuCCT1 (cholangiocarcinoma) cells was studied through a tetrazolium dye reduction assay." | 1.42 | Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability. ( Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M, 2015) |
| "Sorafenib treatment of three human CCA cell lines resulted in Tyr(705) phospho-STAT3 dephosphorylation." | 1.35 | Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. ( Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW, 2009) |
| "Sorafenib treatment dose-dependently blocked growth-factor-induced activation of the MAPKP and inhibited the proliferation of EGI-1 and TFK-1 CC cells in a time- and dose-dependent manner." | 1.34 | Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.00) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Varnier, R | 1 |
| Puszkiel, A | 1 |
| Tod, M | 1 |
| Calattini, S | 1 |
| Payen, L | 1 |
| Lopez, J | 1 |
| Guitton, J | 1 |
| Schwiertz, V | 1 |
| Fontaine, J | 1 |
| Peron, J | 1 |
| Maillet, D | 1 |
| Tartas, S | 1 |
| Bonnin, N | 1 |
| Colomban, O | 1 |
| Augu-Denechere, D | 1 |
| Freyer, G | 1 |
| You, B | 1 |
| Yokoi, K | 1 |
| Kobayashi, A | 1 |
| Motoyama, H | 1 |
| Kitazawa, M | 1 |
| Shimizu, A | 1 |
| Notake, T | 1 |
| Yokoyama, T | 1 |
| Matsumura, T | 1 |
| Takeoka, M | 1 |
| Miyagawa, SI | 1 |
| He, AR | 1 |
| Cohen, RB | 1 |
| Denlinger, CS | 1 |
| Sama, A | 1 |
| Birnbaum, A | 1 |
| Hwang, J | 1 |
| Sato, T | 1 |
| Lewis, N | 1 |
| Mynderse, M | 1 |
| Niland, M | 1 |
| Giles, J | 1 |
| Wallin, J | 1 |
| Moser, B | 1 |
| Zhang, W | 1 |
| Walgren, R | 1 |
| Plimack, ER | 1 |
| Herraez, E | 1 |
| Lozano, E | 1 |
| Macias, RI | 1 |
| Vaquero, J | 1 |
| Bujanda, L | 1 |
| Banales, JM | 1 |
| Marin, JJ | 1 |
| Briz, O | 1 |
| Kim, DH | 1 |
| Jeong, YI | 1 |
| Chung, CW | 1 |
| Kim, CH | 1 |
| Kwak, TW | 1 |
| Lee, HM | 1 |
| Kang, DH | 1 |
| Dokduang, H | 1 |
| Juntana, S | 1 |
| Techasen, A | 1 |
| Namwat, N | 1 |
| Yongvanit, P | 1 |
| Khuntikeo, N | 1 |
| Riggins, GJ | 1 |
| Loilome, W | 1 |
| Lee, JK | 1 |
| Capanu, M | 1 |
| O'Reilly, EM | 1 |
| Ma, J | 1 |
| Chou, JF | 1 |
| Shia, J | 1 |
| Katz, SS | 1 |
| Gansukh, B | 1 |
| Reidy-Lagunes, D | 1 |
| Segal, NH | 1 |
| Yu, KH | 1 |
| Chung, KY | 1 |
| Saltz, LB | 1 |
| Abou-Alfa, GK | 1 |
| Tomuleasa, C | 1 |
| Cucuianu, A | 1 |
| Aldea, M | 1 |
| Berindan-Neagoe, I | 1 |
| El-Khoueiry, AB | 2 |
| Rankin, C | 1 |
| Siegel, AB | 1 |
| Iqbal, S | 1 |
| Gong, IY | 1 |
| Micetich, KC | 1 |
| Kayaleh, OR | 1 |
| Lenz, HJ | 2 |
| Blanke, CD | 2 |
| Seino, S | 1 |
| Tsuchiya, A | 1 |
| Watanabe, M | 1 |
| Edeline, J | 1 |
| Coulouarn, C | 1 |
| Crouzet, L | 1 |
| Pracht, M | 1 |
| Lepareur, N | 1 |
| Clément, B | 1 |
| Garin, E | 1 |
| Barat, S | 1 |
| Bozko, P | 1 |
| Chen, X | 1 |
| Scholta, T | 1 |
| Hanert, F | 1 |
| Götze, J | 1 |
| Malek, NP | 1 |
| Wilkens, L | 1 |
| Plentz, RR | 1 |
| Ding, X | 2 |
| Chaiteerakij, R | 1 |
| Moser, CD | 1 |
| Shaleh, H | 1 |
| Boakye, J | 1 |
| Chen, G | 1 |
| Ndzengue, A | 1 |
| Li, Y | 1 |
| Zhou, Y | 1 |
| Huang, S | 1 |
| Sinicrope, FA | 1 |
| Zou, X | 1 |
| Thomas, MB | 1 |
| Smith, CD | 1 |
| Roberts, LR | 1 |
| Li, H | 1 |
| Zhang, Z | 1 |
| Zhou, Z | 1 |
| Zhou, G | 1 |
| Luo, X | 1 |
| Jia, W | 1 |
| Huang, Z | 1 |
| Li, X | 1 |
| Xing, B | 1 |
| Jiang, X | 1 |
| Li, J | 1 |
| Si, A | 1 |
| Yang, T | 1 |
| Gao, C | 1 |
| Lau, WY | 1 |
| Shen, F | 1 |
| LaRocca, RV | 1 |
| Hicks, MD | 1 |
| Mull, L | 1 |
| Foreman, B | 1 |
| Wang, C | 1 |
| Maass, T | 1 |
| Krupp, M | 1 |
| Thieringer, F | 1 |
| Strand, S | 1 |
| Wörns, MA | 1 |
| Barreiros, AP | 1 |
| Galle, PR | 1 |
| Teufel, A | 1 |
| Blechacz, BR | 1 |
| Smoot, RL | 1 |
| Bronk, SF | 1 |
| Werneburg, NW | 1 |
| Sirica, AE | 1 |
| Gores, GJ | 1 |
| Bengala, C | 1 |
| Bertolini, F | 1 |
| Malavasi, N | 1 |
| Boni, C | 1 |
| Aitini, E | 1 |
| Dealis, C | 1 |
| Zironi, S | 1 |
| Depenni, R | 1 |
| Fontana, A | 1 |
| Del Giovane, C | 1 |
| Luppi, G | 1 |
| Conte, P | 1 |
| Huang, FK | 1 |
| Shi, Z | 1 |
| Pinter, M | 1 |
| Sieghart, W | 1 |
| Reisegger, M | 1 |
| Wrba, F | 1 |
| Peck-Radosavljevic, M | 1 |
| Sugiyama, H | 1 |
| Onuki, K | 1 |
| Ishige, K | 1 |
| Baba, N | 1 |
| Ueda, T | 1 |
| Matsuda, S | 1 |
| Takeuchi, K | 1 |
| Onodera, M | 1 |
| Nakanuma, Y | 1 |
| Yamato, M | 1 |
| Yamamoto, M | 1 |
| Hyodo, I | 1 |
| Shoda, J | 1 |
| Rankin, CJ | 1 |
| Ben-Josef, E | 1 |
| Gold, PJ | 1 |
| Hamilton, RD | 1 |
| Govindarajan, R | 2 |
| Eng, C | 1 |
| Faris, JE | 1 |
| Zhu, AX | 1 |
| Richly, H | 1 |
| Kupsch, P | 1 |
| Passage, K | 1 |
| Grubert, M | 1 |
| Hilger, RA | 1 |
| Voigtmann, R | 1 |
| Schwartz, B | 1 |
| Brendel, E | 1 |
| Christensen, O | 1 |
| Haase, CG | 1 |
| Strumberg, D | 1 |
| Adusumilli, J | 1 |
| Baxter, DL | 1 |
| El-Khoueiry, A | 1 |
| Harik, SI | 1 |
| Huether, A | 2 |
| Höpfner, M | 2 |
| Baradari, V | 2 |
| Schuppan, D | 2 |
| Scherübl, H | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of LY2801653 in Patients With Advanced Cancer[NCT01285037] | Phase 1 | 190 participants (Actual) | Interventional | 2009-09-09 | Completed | ||
| Expanded Access to ABC-108, A Phase IIA Study of ABC294640 in the Treatment of Patients With Advanced,Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma[NCT03414489] | 0 participants | Expanded Access | Available | ||||
| A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma[NCT03377179] | Phase 2 | 65 participants (Actual) | Interventional | 2018-03-07 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for niacinamide and Cholangiocarcinoma
| Article | Year |
|---|---|
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2012 |
8 trials available for niacinamide and Cholangiocarcinoma
| Article | Year |
|---|---|
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Everolimus; Fe | 2023 |
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell | 2019 |
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile | 2013 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile D | 2014 |
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administrati | 2017 |
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bilia | 2010 |
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Diseas | 2012 |
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Area Under Curve; Benzenesulfonates | 2004 |
19 other studies available for niacinamide and Cholangiocarcinoma
| Article | Year |
|---|---|
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug R | 2018 |
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; | 2013 |
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cel | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western | 2013 |
Sorafenib for the treatment of solid malignancies: what about the cancer microenvironment?
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; D | 2013 |
A rare primary liver tumor that responded to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3 | 2014 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy | 2015 |
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts; Cell Line, Tumor; Cell P | 2016 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug | 2016 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug | 2016 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug | 2016 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug | 2016 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Chol | 2016 |
Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
Topics: Adult; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; | 2007 |
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Bi | 2009 |
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tum | 2009 |
[Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Cell Line, Tumor; Cholangioc | 2010 |
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Humans; Liver Neoplasms; Male; N | 2011 |
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intra | 2011 |
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cholangiocarcinoma; Clinical Trials as Topic; Enzyme Inh | 2006 |
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; | 2007 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic | 2007 |